Tag: Cost Plus Drugs

“This Should Be Illegal,” Mark Cuban on U.S. Healthcare (Ep. 49)

“This Should Be Illegal,” Mark Cuban on U.S. Healthcare (Ep. 49)

Episode Overview

In this episode of The Benefit Whisperer, Ralph Weber sits down with Mark Cuban, David Scheinker, and Dr. Kevin Schulman to expose how healthcare pricing really works in the United States.

This is not theory.

It’s a direct look at:

  • Facility fees
  • 340B program dynamics
  • Insurance-driven pricing
  • And why patients and employers rarely know what they’ll pay

At one point, Cuban compares healthcare billing to:

Charging $3 for a beer… and $5,000 for the cup.

Key Topics 

Healthcare Pricing & Transparency

  • Why medical pricing is often unknown until after care
  • How contracts define process, not actual payment amounts

Insurance & Incentives

  • How insurers and intermediaries profit from complexity
  • Why delays, denials, and negotiations are built into the system

Hospital Revenue Models

  • The role of facility fees in cost inflation
  • How programs like 340B influence pricing behavior

Employer Impact

  • Why employers are funding the system, but lack visibility and control
  • The disconnect between plan design and actual outcomes

Potential Solutions

  • Direct contracting models
  • Transparent pricing strategies
  • Simplified, digitally defined agreements

Key Takeaway 

The U.S. healthcare system is not unpredictable by accident. It’s structured in a way where complexity and lack of transparency directly support revenue generation.

Guests & Contact Information

Ralph Weber
Host, The Benefit Whisperer
🌐 https://mybenefitssuck.com

📧ralph@thebenefitwhisperer.com

Mark Cuban
Founder, Cost Plus Drugs
📧 mark@costplusdrugs.com

Dr. David Scheinker
Executive Director of Systems Design and Collaborative Research, Stanford Lucile Packard Children’s Hospital
Founder & Director, SURF (Stanford Medicine)
🌐www.surf.stanford.edu

📧 www.linkedin.com/in/david-scheinker/

Kevin Schulman
Professor of Medicine and Health Policy, Stanford University
Faculty Director, Stanford Clinical Excellence Research Center
📧 kevin.schulman@stanford.edu

Produced by Kathrine Mowrey (Content & Distribution)

The “HOME TEAM” Gets Paid 160x MORE. Is That Fair? (Ep. 45)

The “HOME TEAM” Gets Paid 160x MORE. Is That Fair? (Ep. 45)

In this episode of The Benefit Whisperer, Ralph Weber examines Tennessee’s proposed legislation, SB 2040 and HB 1959, aimed at preventing pharmacy benefit managers (PBMs) from owning pharmacies.

An audit from the Tennessee Department of Commerce & Insurance found instances where a major PBM allegedly reimbursed its own pharmacy up to 16,000% more than independent pharmacies for the same drug. One example cited showed reimbursement of approximately $9,000 versus $57 for identical medication quantities.

Independent pharmacist and healthcare policy advocate Benjamin Jolley explains:

• The structure of SB 2040 and HB 1959
• How these bills mirror Arkansas Act 624
• The economic impact of PBM vertical integration
• What AWP and reimbursement pricing really mean
• Why small employers and self-funded plans could bear the cost
• Legal challenges surrounding similar legislation

This episode explores healthcare market concentration, employer plan costs, and patient access issues through a fact-based policy discussion.

If you’re responsible for healthcare spend, this conversation deserves your attention.

Subscribe for direct, unfiltered conversations exposing waste in healthcare.

🎙 Hosted by Ralph Weber
📌 The Benefit Whisperer